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 Introduction 
 
Treatment of patients with chronic heart failure has been an area of great interests, 
because the prognosis in heart failure remains to be poor despite novel therapeutic 
modalities. Among various causes in heart failure, myocardial infarction is the most 
common and novel therapeutic modalities for heart failure are much needed. 
Researchers have recently focused on the novel therapeutic field of cardiac regeneration 
induced by transplantation of embryonic stem cells, mesenchymal cells, bone marrow 
cells, or myoblasts and the administration of granulocyte-colony stimulating factor 
(G-CSF).  
Previous studies have shown that cardiomyocytes are efficiently and remarkably 
transdifferentiated from transplanted progenitor cells derived from bone marrow cells. 
However, recent studies have revealed that the regeneration rate from progenitor cells to 
cardiomyocytes is quite low and they frequently fuse with resident cardiomyocytes, and 
that the actual transdifferentiation rate is extremely low not enough to improve the 
entire cardiac function after the regeneration therapy if transdifferentiation alone could 
be involved in the situation [14]. Surprisingly, however, such treatments in fact 
improve the function by unknown mechanisms. Even with treatments using G-CSF, it 
has been also reported that the transdifferentiation rate is quite low, but that cardiac 
function is markedly improved [5,6]. Recently it has been reported that G-CSF has a 
direct effect on cardiomyocytes through the receptor responsible for cardiac 
hypertrophy and inhibits both apoptosis and remodeling in the failing heart following 
myocardial infarction [7]. 
It is important to consider two of key factors affecting survival rate in patients with 
chronic heart failure, i.e., suppression of the progression of cardiac remodeling and 
suppression of the fatal arrhythmia. As an elegant previous study demonstrates, G-CSF 
inhibits cardiac remodeling, resulting in survival rate improvement [7]. However, it 
remains to be investigated whether G-CSF has an anti-arrhythmia effect, because the 
study referred to did not investigate this indetail. Furthermore, there are no reports that 
reveal the detailed molecular mechanisms of the anti-arrhythmia effect of G-CSF.  
Connexin (Cx) 43, a component of the gap junction complex, has recently been 
reported to be involved in modulating arrhythmia, The survival of Cx43 knockout mice 
was lower than that of wild-type mice because of greater susceptibility to lethal 
arrhythmia, including ventricular tachycardia and fibrillation. This suggests that Cx43 
plays a crucial role in modulating arrhythmia [811]. We recently demonstrated in rats 
that acetylcholine (ACh) activates the function of gap junctions by sustaining the Cx43 
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protein level leading to inhibition of the lethal arrhythmia that follows myocardial 
infarction [12]. 
In the present study, we assessed the hypothesis that G-CSF has an anti-arrhythmia 
effect apart from its anti-apoptotic effect, through the sustainable localization of Cx43 
on the plasma membrane, leading to an additive contribution to the increased survival 
rate following the ischemic heart diseases. 
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Materials and Methods 
Cell Culture 
To examine the effect of G-CSF on cardiomyocytes, we used primary cardiomyocytes 
isolated from neonatal rats and H9c2 cells. H9c2 cells are frequently used to investigate 
signal transduction and channels instead of rat primary cardiomyocytes. H9c2 cells have 
an advantage to be more efficiently gene-transferred than primary cardiomyocytes, 
therefore, in the present study H9c2 cells were used especially for a reporter assay. 
H9c2 cells were incubated in DMEM containing 10% FBS and antibiotics. Rat primary 
cardiomyocytes were isolated from 2- to 3-day-old neonatal Wistar rats and incubated in 
DMEM/Ham F-12 containing 10% FBS and ITS supplement. HEK293 cells were used 
in gene transfection studies; they were cultured in DMEM containing 10% FBS. 
 
Western Blot Analysis 
Rat primary cardiomyocytes or H9c2 cells were treated with 10 ng/ml of G-CSF to 
evaluate their protein expression level under normoxic or hypoxic conditions with 1 
mM of cobalt chloride (CoCl2) or an oxygen concentration of 1%. In the case of 
hypoxia, cardiomyocytes were pretreated with G-CSF 24 h before hypoxia, followed by 
12 h of hypoxic treatment. Cell lysates were mixed with a sample buffer, fractionated by 
SDS-PAGE and transferred onto membranes. The membranes were incubated with 
polyclonal primary antibodies against G-CSF receptor, phospho-JAK2 (Santa Cruz 
Biotechnology, Santa Cruz, CA), E-catenin (Cell Signaling Technology, Beverly, MA) 
or Cx43 (ZYMED Laboratories Inc., South San Francisco, CA), and monoclonal 
antibodies against D-tubulin (Lab Vision, Fremont, CA), phosphor-Akt (Cell Signaling 
Technology, Beverly, MA, USA) or pan-cadherin (Sigma Chemical Co., St. Louis, MO). 
They were then reacted with an HRP-conjugated secondary antibody (BD Transduction 
Laboratories, San Diego, CA, USA, and Promega, Madison, WI). Positive signals were 
detected with an enhanced chemiluminescence system (Amersham, Piscataway, NJ). In 
each study, experiments were performed in duplicate and repeated four or five times 
(n=4 or 5). Only representative data alone are shown.  
 
MTT Activity Assay 
To evaluate the effects of hypoxia on the mitochondrial function of cardiomyocytes, we 
measured the reduction activity of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) in cardiomyocytes under hypoxic conditions in the presence or absence 
of G-CSF. The cells were pretreated with 10 ng/ml G-CSF for 24 h and then subjected 
to 12-h hypoxia. One hour before sampling, the MTT reagents were added to the culture 
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and incubated; and absorbance at 450 nm was measured (Cell Counting Kit-8; Dojindo, 
Kumamoto, Japan). 
 
Myocardial infarction in rats  
Left ventricular myocardial infarction was induced by left coronary artery ligation in 
anesthetized male Wistar rats, which were ventilated artificially. G-CSF (5 Pg/kg) was 
administered intraperitoneally 24 h before coronary ligation. For 30 min after the 
coronary ligation, ECG was recorded to evaluate arrhythmia, and blood pressure was 
also monitored in rats with or without G-CSF treatment (no treatment, n=4; G-CSF 
treatment, n=7). 
 
Transfection 
To investigate whether G-CSF regulates Wnt signaling, the reporter vector of TOPflash 
(Upstate Cell Signaling Solutions, Lake Placid, NY) was used for transfection into 
H9c2 cells. The reporter vector possesses three copies of the T-cell factor binding site. 
H9c2 cells were transfected together with TOPflash vector and SeaPansy vector by 
Effectene (Quiagen, Valencia, CA) according to the manufacturer’s protocol. After 24 h 
of transfection, G-CSF (10 ng/ml) was added. Transfected cells were lysed 24 h later, 
and the luciferase activity was evaluated with a dual luciferase activity assay kit from 
Wako Chemical (Tokyo, Japan). 
 
Immunocytochemistry 
Rat primary cardiomyocytes were fixed with 4% paraformaldehyde for 10 min and 
permeabilized with 0.1% Triton X-100 for 10 min. Then, cells were incubated with 4% 
skim milk and successively incubated with an anti-Cx43 polyclonal antibody (ZYMED 
Laboratories Inc.), anti-E-catenin polyclonal antibody (Cell Signaling Technology) or 
anti-pan-cadherin monoclonal antibody (Sigma Chemical Co.), in 1% skim milk at 4ºC 
overnight, followed by FITC or Cy3-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories, West Grove, PA) at 4ºC overnight. After mounting, 
imaging of the immunoreactivities were examined and obtained with an OLYMPUS 
FLUOVIEW 300 laser-scanning confocal microscope (OLYMPUS, Tokyo, Japan).  
 
RT-PCR 
Total RNA was isolated from primary cardiomyocytes according to a modified acid 
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guanidinium-phenol-chloroform method using an RNA isolation kit (ISOGEN; Nippon 
Gene, Tokyo, Japan) and was reverse-transcribed to obtain a first-strand cDNA. This 
first-strand cDNA was amplified by specific primers, and the PCR products were 
fractionated by electrophoresis. 
 
Functional analysis of gap junctions using a scrape/scratch or microinjection method 
A scrape-loading method was used to introduce macromolecules into cultured cells by 
inducing a transient tear in the plasma membrane, thereby allowing sensitive 
determination of cell-cell communication. Following treatment with 10 ng/ml G-CSF 
for 24 h, 1% Lucifer Yellow was applied to the center of the coverslip, on which 
cardiomyocytes were cultured. A 27-gauge needle was used to create two longitudinal 
scratches through the cell monolayer. One minute later, the cardiomyocytes were 
washed and finally examined by Axiovert fluorescence microscopy (Carl Zeiss, Inc.). 
Lucifer Yellow is transmitted from one cell to another, presumably across patent gap 
junctions [1316]. The area of the dye transferred from the scratched margin in hypoxia 
or hypoxia with G-CSF treatment was semiquantified using the NIH image system and 
compared with that in normoxia. In another dye transfer assay using a microinjection 
method, LY was injected electrophoretically via a conventional microelectrode made 
from glass capillaries using micromanipulator system (SURUGA SEIKI Co, Ltd., 
Shizuoka, Japan). The outer diameter of microelectrodes was 0.15 to 0.25 Pm. An 
inward square-pulse current of 100 msec. duration was injected at 2 Hz for 1 minute 
using a voltage pulse generator (SEN7203, NIHON KONDEN, Tokyo, Japan). In this 
microinjection, experiments could not be practically conducted in a hypoxic chamber, 
therefore, a chemical hypoxic reagent of CoCl2 (1 mM) was used to induce cellular 
hypoxia. 
 
Electrophysiological evaluation of the G-CSF effect on cardiomyocytes during 
hypoxia using mitochondrial membrane potential dye 
Rat primary cardiomyocytes were pretreated with 10 ng/ml G-CSF for 24 h, followed 
by 1% hypoxia for 1 h. During hypoxia, the cardiomyocytes were incubated with 2 PM 
di-4-ANEPPS 
(pyridinium,4-{2-[6-(dibutylamino)-2-naphthalenyl]ethenyl}-1-(3-sulfopropyl)-hydroxi
de) for 15 min followed by washing. In the presence of cytochalasin D (5 PM), during 
hypoxic conditions with or without G-CSF, the cardiomyocytes were observed to 
evaluate the propagation of action potentials, using an imaging system for 
opto-electrophysiology, MiCAM02 (Brainvision, Tokyo, Japan).  
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Densitometry 
The western blotting data were analyzed using Kodak 1D Image Analysis Software 
(Eastman Kodak Co., Rochester, NY). 
 
Statistics 
The data are presented as means r S.E (standard error).  Mean values between two 
groups were compared using the unpaired Student’s t test. Multiple comparisons of 
results were assessed by ANOVA for multiple comparisons of results. Differences were 
considered significant at P < 0.05. 
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Results 
 
G-CSF transduces the signal through its receptor in cardiomyocytes 
The expression level of G-CSF receptor (G-CSFR) was examined by Western blot 
analysis. As shown in Figure 1, G-CSFR was detected in rat primary cardiomyocytes 
with a molecular weight of 130 kDa. To investigate whether the G-CSFR was functional 
in cardiomyocytes, we evaluated signal transduction through JAK2 phosphorylation, 
one of the major signaling molecules for G-CSFR. As shown in Figure 1, G-CSF (10 
ng/ml) increased JAK2 phosphorylation in cardiomyocytes. Likewise, JAK2 was also 
phosphorylated in H9c2 cells, cell lines of rat ventricular myocytes, by G-CSF 
suggesting that H9c2 cells are equipped with the similar machinery responding G-CSF. 
As a result, along with the JAK2 phosphorylation, an important signal responsible for 
cardiac hypertrophy, G-CSF actually increased cell size within 24 h (365.2 r 22.2%, #P 
< 0.01 vs. control, n=6) comparably with 1 PM ET-1 (287.2 r 35.3%, #P < 0.01 vs. 
control, n=6). A similar effect was also observed in H9c2 cells (data not shown). 
Although a G-CSFR-specific receptor antagonist is not available, taken together with 
the fact that JAK2 is known to be a G-CSFR-related molecule, it is suggested that 
G-CSF acts on cardiomyocytes through its receptor. 
 
G-CSF has a cell survival effect on cardiomyocytes during hypoxic condition 
To study whether G-CSF has a cell survival effect on rat primary cardiomyocytes, we 
first examined Akt phosphorylation, a cell survival signal, in response to G-CSF. As 
demonstrated in Figure 2, Akt was phosphorylated by G-CSF (10 ng/ml) within 4 h, 
suggesting that G-CSF plays a role in transducing a cell survival signal. To investigate 
whether G-CSF actually possesses such a cell-protective effect, cardiomyocytes were 
treated with 1 mM CoCl2, a hypoxic reagent, for 8 h following the 24-h G-CSF 
pretreatment. With CoCl2 alone, cell viability, which was evaluated with the MTT 
reduction assay, was markedly reduced in the absence of G-CSF. However, the G-CSF 
pretreatment sustained cell viability even in the presence of CoCl2 (n=6, P < 0.001 vs. 
CoCl2) for 8 h. This suggests that G-CSF has a cell-protective effect. 
 
G-CSF shows an anti-arrhythmia effect on acute myocardial infarction 
It has been reported that G-CSF has a chronic effect on myocardial infarcted rats, 
leading to an increase in the survival rate of rats with chronic myocardial infarction, and 
it has been speculated that this effect probably occurs through inhibition of cardiac 
remodeling, i.e. inhibition of death due to chronic cardiac pump failure. However, the 
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effects of G-CSF on suppression of fetal arrhythmia in the chronic stage were not fully 
investigated. Furthermore, an acute effect of G-CSF on the infarcted heart has not yet 
been profoundly studied, especially the effect of G-CSF on arrhythmogenesis in acute 
myocardial infarction. Therefore, we performed an in vivo study to investigate whether 
G-CSF pretreatment has an anti-arrhythmia effect on the myocardial infarcted heart.  
 Rats were pretreated or not pretreated with 5 Pg/kg G-CSF 24 h before the left 
coronary artery ligation. Without G-CSF treatment, all rats suffered from ventricular 
arrhythmia. As demonstrated in Figure 3A, a G-CSF-untreated rat abruptly showed a 
decrease in blood pressure due to ventricular fibrillation (VF), however, the treated rat 
sustained blood pressure during the entire time course. Especially, VF was usually 
observed within 30 minutes after the coronary ligation (100%), with a lethal episode in 
some rats because of sustained VF. In contrast, the G-CSF-pretreated rats suffered less 
frequently from ventricular arrhythmia. Specifically, VF was never detected in the 
G-CSF-treated rats (0%). In rats treated with G-CSF, the phosphorylated forms of Cx43 
protein in the hearts was greatly increased, compared with those non-treated hearts 
(Figure 3A). Furthermore, G-CSF also reduced the other arrhythmia parameter, the 
duration of ventricular tachycardia (VT) (10.9 r 2.3 vs. 58.7 r 3.4 sec, P < 0.01). These 
results suggest that G-CSF is involved in inhibiting arrhythmia induced by myocardial 
infarction. 
 
G-CSF activates Wnt signal in cardiomyocytes 
To further clarify the anti-arrhythmia mechanism of G-CSF, we first focused on the Wnt 
signal, which is involved in cell-cell communication as well as cell survival. Therefore, 
the Wnt signal was examined in cardiomyocytes in response to G-CSF. As shown in 
Figure 4A, H9c2 cells were transfected with the TOPflash luciferase vector and 
SeaPansy vector for dual luciferase evaluation system. Luciferase activity was increased 
by G-CSF up to 10.1- and 25.9-fold following the 24- and 36-h treatments, respectively 
(#P < 0.01 vs. 0h). In accordance with this result, E-catenin protein expression was 
greatly increased by G-CSF in whole cell lysates from both H9c2 cells and primary 
cardiomyocytes (292.6 r 14.4 %, #P < 0.01 and 437.0 r 10.3 %, #P < 0.01, 
respectively) (Figure 4B). Since E-catenin is known to be regulated by a negative 
regulator of Wnt signal GSK-3E, which phosphorylates E-catenin and accelerates 
degradation of the protein, it is suggested that G-CSF activates the Wnt signal in 
cardiomyocytes, resulting in inhibition of E-catenin degradation.  
 
G-CSF inhibits degradation of Cx43 
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According to our results, we speculated that G-CSF plays an important role in inhibiting 
the degradation of protein other than E-catenin through Wnt signal activation. Therefore, 
we examined whether G-CSF increased the Cx43 protein level. Cx43 is also known to 
possess a shorter protein half-life and rapidly regulated by the protein degradation 
system. 
Initially Cx43 mRNA expression level was evaluated by RT-PCR. As shown in Figure 
5, the Cx43 mRNA level was not increased by G-CSF. In contrast, the total Cx43 
protein level was markedly increased by G-CSF in rat primary cardiomyocytes. 
Specifically, a Cx43 phosphorylated form, which was composed of upper two bands 
designated as P-Cx43 in Figure 5, was more increased by G-CSF. The lower band 
designated as a non-phosphorylated band (N-Cx43 in Figure 5) was also up-regulated 
by G-CSF.  
To further elucidate the effect of G-CSF on the localization of gap junction 
components on the cell surface, an immunocytochemical study was conducted using 
antibodies against E-catenin, pan-cadherin and Cx43 and it was also investigated 
whether the components had any mutual interaction. Such G-CSF-increased E-catenin 
signals overlapped, especially on the plasma membrane, with those of Cx43 (Figure 6), 
and it was colocalized with increased signals of cadherin, which was also evident by 
Western blot analysis (Figure 6), suggesting that G-CSF increases protein levels of gap 
junction components, including E-catenin, cadherin, and Cx43, and that the localization 
of these components on the cytoplasmic membrane is tightly regulated by G-CSF. 
 
G-CSF functionally activates the gap junction in primary cardiomyocytes 
To further study whether G-CSF modulates the function of gap junctions, a dye transfer 
study was conducted using Lucifer Yellow with a scrape/scratch or microinjection 
method. Hypoxia decreased the gap junction function along with reduction in dye 
transfer, compared with normoxia, demonstrating that gap junction was impaired by 1% 
of hypoxia (Figure 7A). However, pretreatment with G-CSF inhibited the reduction of 
dye transfer, and the transfer level during hypoxia was sustained at a level similar to that 
in normoxia by G-CSF (Figure 7A). A microinjection method also indicated that 
hypoxia induced by 1 mM of CoCl2 decreased dye transfer, resulting in the dye 
remaining in the cell. In this microinjection, chemical hypoxic reagent CoCl2 was used 
instead of 1% hypoxia, because microinjection could not be practically performed in a 
hypoxic chamber. However, G-CSF treatment resulted in recovery of cell-cell 
communication even during hypoxia (Figure 7B). This suggests that G-CSF regulates 
gap junction to enhance cell-cell communication through the stabilization of gap 
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junction components to the plasma membrane. This may contribute to the 
anti-arrhythmia effect. 
 To investigate the electrophysiological effects of G-CSF on gap junctions, the 
propagation of membrane potential in cardiomyocytes was evaluated using 
Di-4-ANEPPS 
(pyridinium,4-{2-[6-(dibutylamino)-2-naphthalenyl]ethenyl}-1-(3-sulfopropyl)-hydroxi
de). As demonstrated in Figure 8, in the absence of G-CSF, the activation and 
propagation of the action potential was dampened by hypoxia. In contrast, in 
G-CSF-pretreated cardiomyocytes, activation and propagation of the membrane 
potential were sustained even in hypoxia, suggesting that G-CSF sustains gap junction 
function even during hypoxia.  
 Taken these results together, we suggest that G-CSF inhibits the impairment of the gap 
junction function during hypoxia by sustaining the protein levels of the components in 
cardiomyocytes. Therefore, the use of G-CSF could lead to an anti-arrhythmia effect on 
cardiomyocytes during hypoxia. 
 
 
 12 
Discussion 
 
In contrast with the previous studies using G-CSF, the present study demonstrates a 
novel function of G-CSF. We demonstrate that G-CSF stabilizes the gap junction 
complex through the Wnt signal to sustain its function even under hypoxic conditions. 
Therefore, we suggest that G-CSF inhibits impairment of the gap junction function and 
has the potency to suppress ventricular arrhythmia after acute myocardial ischemia and 
may be used as a therapeutic tool. 
 In the present study, we initially demonstrate that G-CSF has a direct effect on 
cardiomyocytes through G-CSFR with activation of JAK2 signal transduction, as 
reported in previous studies [7], and that G-CSF also plays a pivotal role in increasing 
the protein expression levels of E-catenin and Cx43. E-catenin is known to be involved 
in regulating the gap junction complex and other membrane-associated molecules 
including cadherin. These are also known to be indispensable for gap junction complex 
formation [1721]. In accordance with this, the Wnt signal is activated by G-CSF, as 
demonstrated by TOPflash reporter assay. Activation of the Wnt signal, resulting in 
increased E-catenin levels, as found in this study, is also reported to be responsible for 
cell survival [2224]. It also reveals that G-CSF protects cells against chemical hypoxic 
stress. The results can be combined to suggest that G-CSF plays a role in 
cardioprotection through the survival pathway of the Wnt signal.  
 Furthermore, this study reveals a novel G-CSF function acting through E-catenin. 
Besides the cell survival signal, G-CSF increases cell-cell communication by inhibiting 
Cx43 protein degradation and increasing the cadherin level as shown in Figure 6, 
resulting in increased expression levels of gap junction components. These effects are 
confirmed by the sustained dye transfer in cardiomyocytes even during hypoxia in the 
presence of G-CSF alone, as shown in scrape/scratch and microinjection experiments. 
These in vitro data are also confirmed by a rat model of acute myocardial ischemia with 
a reduced frequency of ventricular tachycardiac arrhythmia after G-CSF treatment. 
Therefore, from the results of the present study, we suggest that G-CSF has another 
novel effect of anti-arrhythmia through the activation of gap junction function. 
 Many studies have been performed on the pathogenesis of arrhythmia [25-27]. 
Recently the impairment of gap junction function has been focused on as one of the 
pathogenic features [8-11]. Since heterogeneity of conduction velocity is induced by 
hypoxia through impairment of gap junctions, it is considered that impairment of gap 
junctions is responsible for one of the arrhythmogenic substrates. Specifically, Cx43 
knockout mice are reported to be remarkably susceptible to ventricular arrhythmia, 
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causing sudden death [9]. In addition, our recent works have revealed that acetylcholine 
plays a pivotal role in sustaining the Cx43 protein level during hypoxia and that vagal 
nerve stimulation inhibits arrhythmia induced by acute myocardial infarction by 
sustaining the Cx43 protein level [12,28]; this suggests that intact gap junction function 
is necessary for the inhibition of arrhythmia. Based on these studies, it is suggested that 
a drug that increases the Cx43 protein expression level or sustains its appropriate 
localization might provide a therapeutic tool for arrhythmia in addition to currently 
available anti-arrhythmia drugs.  
The present study suggests a precise mechanism for the regulation of Cx43 protein 
level by G-CSF, which activates Wnt signal, leading to stabilization of the protein 
localization on plasma membrane along with other membrane-associated molecules and 
to improvement of gap junction function. There are no studies clearly demonstrating a 
precise link between G-CSF, Wnt signal and the anti-arrhythmia effect, therefore, the 
present study was performed. However, several previous studies suggest each link, i.e. 
Wnt signal and Cx43. The present results are compatible with the study demonstrating 
that activation of the Wnt signal by lithium chloride in cardiomyocytes causes an 
increase in the Cx43 protein level [29]. Other studies also reveal that the activated Wnt 
signal increases cell aggregation, which is resistant to agitation, suggesting an increase 
in intercellular communication [30,31]. These findings indicate that Wnt signal 
activation accelerates cell-cell interaction through molecules involved in gap junction 
formation. Gap junctions are composed of connexin subtypes and are supported by the 
formation of complexes with cadherin and E-catenin [32,33]. E-catenin is located in the 
subcytoplasmic membrane and anchors Cx43 to the membrane [29,30]. It is reported 
that the Cx43 function is modulated by the total protein level as well as the 
phosphorylation level [34] and is also affected by these anchoring molecules. These are 
tightly associated with Cx43, resulting in complex formation, and are essential in 
maintaining the gap junction function, because knockout mice, including cadherin 
knockout mice, show abnormal gap junction function, causing susceptibility to 
arrhythmia [17]. Heterogeneous cadherin knockout mice do not survive as long as 
wild-type mice, because of sudden death; Cx43 localization is also impaired and it is not 
targeted to the plasma membrane, resulting in impairment of the function [17].  
 The present study reveals a novel function of G-CSF and presents a new therapeutic 
insight into arrhythmia. These are based on our results showing that G-CSF activates the 
Wnt signal, and that the Cx43 protein level is sustained during hypoxia by G-CSF. 
Furthermore, the expression levels of Cx43, cadherin, and E-catenin are all increased by 
G-CSF, as is their appropriate localization at the plasma membrane. These results 
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suggest that G-CSF regulates these protein levels and their localization, thereby 
activating their function, and prompts us to speculate that G-CSF actually possesses the 
anti-arrhythmia effects. 
 In vivo studies indicate an anti-arrhythmia effect on the acute ischemic heart. 
Surprisingly, G-CSF efficiently decreases the incidence of lethal ventricular tachycardia 
in rats with myocardial infarction. G-CSF clearly decreases the duration of sustained 
ventricular tachycardia. These effects of G-CSF might contribute to the increased 
survival of rats with acute myocardial infarction, as reported in a recent study [35], 
which only suggests a link between G-CSF and an anti-arrhythmia effect alone, but does 
not reveal the precise mechanisms. Based on other studies using myocardial infarcted 
rats, their findings suggest that G-CSF inhibits cardiomyocytes apoptosis during the 
progression of heart failure [7], accelerates angiogenesis [36], and enhances the 
attenuation of the inflammatory reaction during the acute myocardial infarction [5]. 
Although those speculative aspects of G-CSF are not independent, the new effect of 
G-CSF revealed by the present study may indicate a pivotal role for G-CSF in inhibiting 
arrhythmia by modulating gap junction components. Therefore, our study may provide a 
novel therapeutic indication for the use of G-CSF in patients with myocardial infarction 
in order to inhibit lethal arrhythmia in the acute phase. 
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Figure legends 
 
Figure 1 
G-CSF receptor protein expression is detected in rat primary cardiomyocytes and 
transduces the signal through JAK2 phosphorylation.  
G-CSF receptor was expressed in rat primary cardiomyocytes (A), and G-CSF (10 
ng/ml) phosphorylated JAK2 within 4 hours, one of crucial factors responsible for 
cardiac hypertrophy in rat primary cardiomyocytes and H9c2 cells. Representative data 
are shown from four independent experiments (n=4 in each cell) (B). The G-CSF 
treatment was accompanied by enlargement of cell size (#P < 0.01 vs. control, n=6), the 
extent of which was comparable with that of ET-1 (1 PM) (# P <0.01 vs. control, n=6). 
Bars in the upper panels, 10 Pm; lower panels, 20 Pm (C). 
 
Figure 2 
G-CSF induces Akt phosphorylation and protects cardiomyocytes from a hypoxic 
mimetic. 
Akt was phosphorylated by G-CSF (10 ng/ml) with a longer time course. Representative 
data are shown from four independent experiments. G-CSF-pretreated cardiomyocytes 
(24 h) showed comparable cell viability even with 1 mM CoCl2 for 8 h, evaluated by the 
MTT reduction assay (n=6).  
 
Figure 3 
G-CSF inhibits the occurrence and frequency of ventricular arrhythmia induced by 
acute myocardial infarction. 
A representative time course of blood pressure with or without the G-CSF pretreatment 
is shown. In rats without G-CSF pretreatment, VF occurred in the late phase after 
coronary ligation, causing abrupt reduction of blood pressure, but spontaneously 
attenuated (n=6). The occurrence of ventricular fibrillation (VF) was 100% in the 
non-treated rat. In contrast, G-CSF-treated rats did not show VF (n=7). Furthermore, 
G-CSF increased a phosphorylated Cx43 expression level in the heart. Representative 
Western blot data are shown (1-3, no treatment; 4-6, G-CSF-treatment) (A). In 
accordance with this, G-CSF also decreased the duration of ventricular tachycardia 
(10.9 r 2.3 vs. 58.7 r 3.4 sec., P < 0.01) (B). 
 
Figure 4 
G-CSF activates the Wnt signal in cardiomyocytes through the increased E-catenin level 
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with a slow time course. 
The luciferase activity of TOPflash vector, adjusted by a SeaPansy luciferase activity, 
was increased by 10 ng/ml G-CSF in cardiomyocytes. The G-CSF-induced increase in 
the luciferase activity was evident within 24 h (#P < 0.01 vs. 0h). Representative data 
from four independent experiments are shown (A). The increased luciferase activity 
contributed to elevated E-catenin protein expression (n=4). Both H9c2 cells and primary 
cardiomyocytes increased E-catenin protein expression (#P < 0.01 vs. 0h in each cell 
group) (B). 
 
Figure 5 
The Connexin43 (Cx43) protein expression level is increased by G-CSF, independent of 
the transcriptional regulation, under the normoxic conditions. 
The Cx43 mRNA level was not affected by 10 ng/ml G-CSF within 24 h; however, the 
protein expression level including upper two phosphorylated forms (P-Cx43) and lower 
one (N-Cx43) was increased by G-CSF within 24 h (n=5). In Western blot analysis 
Cx43 is known to be composed of upper bands as phosphorylated forms and lower band 
as non-phosphorylated one. 
 
Figure 6 
G-CSF increased immunoreactivities of E-catenin, cadherin, and Cx43 and increased 
their colocalization under normoxic conditions. 
Primary cardiomyocytes from G-CSF-treated rats showed more immunoreactivities of 
E-catenin, cadherin, and Cx43, compared with non-treated cardiomyocytes, as also 
shown with increased expression of cadherin in Western blot analysis. These 
immunoreactivities overlapped especially in the cytoplasmic membrane. Compared with 
control, distribution of E-catenin was specifically detected on cytoplasmic membrane in 
G-CSF-treated cardiomyocytes. Representative data from six independent experiments 
are shown (n=6). Bars, 20 Pm. 
 
Figure 7 
G-CSF enhances the cell-cell communication as demonstrated by the scrape/scratch and 
microinjection methods. 
Lucifer yellow dye was not efficiently transferred during 1% hypoxia, evaluated by a 
scrape/scratch method (A), and treatment with 1 mM of CoCl2, evaluated by a 
microinjection method (B), compared with normoxia. However, G-CSF pretreatment 
sustained dye transfer at a level similar to that during normoxia (n=5) (A, B) 
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Figure 8 
Propagation of membrane potential in rat primary cardiomyocytes is sustained by 
G-CSF during hypoxia. 
The propagation of the action potential, detected by di-4-ANEPPS, in rat primary 
cardiomyocytes decreased during hypoxia, with a shorter action potential duration and 
lower frequency. However, in G-CSF-pretreated cardiomyocytes the action potential 
propagated comparably with normoxic cardiomyocytes. Duration and frequency were 
not remarkably decreased by hypoxia in G-CSF-treated cardiomyocytes. Representative 
data from five independent experiments are shown (n=5). 
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